BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
296 hedge funds and large institutions have $9.26B invested in bluebird bio in 2017 Q4 according to their latest regulatory filings, with 78 funds opening new positions, 96 increasing their positions, 97 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
296
Holders Change
+53
Holders Change %
+21.81%
% of All Funds
6.72%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
78
Increased
96
Reduced
97
Closed
24
Calls
$256M
Puts
$170M
Net Calls
+$86.9M
Net Calls Change
+$34M
Top Buyers
1 |
Capital World Investors
Los Angeles,
California
|
+$113M |
2 |
![]()
Fidelity Investments
Boston,
Massachusetts
|
+$93.1M |
3 |
Two Sigma Advisers
New York
|
+$79.7M |
4 |
Capital Research Global Investors
Los Angeles,
California
|
+$75.9M |
5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$65.8M |
Top Sellers
1 |
Wellington Management Group
Boston,
Massachusetts
|
-$232M |
2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$53.9M |
3 |
Wells Fargo
San Francisco,
California
|
-$31.5M |
4 |
State Street
Boston,
Massachusetts
|
-$30M |
5 |
UBS AM
Chicago,
Illinois
|
-$27.9M |